Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021

SUMMIT, N.J. , Sept. 29, Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced data supporting the effectiveness of both cell-based and adjuvanted seasonal influenza vaccines from two real-world studies conducted during the 2019/2020 influenza season in the U.S. These analyses will be presented today at the virtual IDWeek 2021 conference.

Read the source article at PR Newswire
2021-09-29 11:30:00